Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma

Autor:	Eunju Hurh, Darren Hargrave, F. Mechinaud, B. Geoerger, Priya Deshpande, Tobey J. MacDonald, Michela Casanova, Eric Bouffet, Simon Bailey, Stacey Kalambakas, Mark W. Kieran, Alba A. Brandes, Julia C. Chisholm, Riccardo Riccardi, Sarah Leary, Isabelle Aerts, Kenneth J. Cohen, Feng Tai, Warren P. Mason
Rok vydání:	2017
Předmět:	Adult Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Pediatrics Adolescent Pyridines Administration Oral Phases of clinical research Sonidegib Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pharmacokinetics Neoplasms Internal medicine medicine Humans Tissue Distribution Young adult Cerebellar Neoplasms Child Aged Medulloblastoma Brain Neoplasms business.industry Biphenyl Compounds Middle Aged Prognosis medicine.disease Biphenyl compound Clinical trial 030104 developmental biology chemistry Child Preschool 030220 oncology & carcinogenesis Female Neurology (clinical) Neoplasm Recurrence Local business Pediatric Neuro-Oncology Progressive disease Follow-Up Studies
Zdroj:	Neuro-Oncology. 19:1542-1552
ISSN:	1523-5866 1522-8517
Popis:	Background: Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and pharmacokinetics of sonidegib in children with relapsed/recurrent tumors followed by a phase II trial in pediatric and adult patients with relapsed medulloblastoma (MB) to assess tumor response. Methods: Pediatric patients aged ≥1 to
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5193152d678baed51559012211bf5734 https://doi.org/10.1093/neuonc/nox109 Zobrazit plný text záznamu